On October 10, 2022, CTI BioPharma Corp. eliminated the position of Chief Operating Officer. Accordingly, Bruce Seeley resigned as Chief Operating Officer, effective as of that date.

In connection with his separation from the company, Mr. Seeley will be entitled to payment of severance benefits pursuant to his severance agreement with the Company (filed as Exhibit 10.11 to the Company's Form 10-K for the year ended December 31, 2015). The Company wishes to acknowledge Mr. Seeley's contributions to the approval and launch of VONJO and is supportive of his pursuit of senior leadership opportunities. As the commercialization of VONJO transitions from the initial launch phase, Jim Fong, the Company's Chief Commercial Officer, has been promoted to Executive Vice President and Chief Commercial Officer, and will begin reporting directly to the Company's Chief Executive Officer.

The management functions of the former Chief Operating Officer role have been reassigned to other members of the senior management team.